Vial Doses First Patient with Asthma in Phase 1b Study of Vial’s IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing

San Francisco, California — October 5, 2026 – Vial, a clinical-stage biotechnology company, today announced that it has dosed the first patient in its Phase 1b clinical study of Vial’s IL-13 x TSLP in patients with mild-to-moderate asthma. Vial’s IL-13 x TSLP is a novel, half-life-extended bispecific antibody in development for the treatment of asthma and […]